De-Risk & Accelerate Your Journey To The Clinic With Your Cell Therapy CDMO Partner
Cell therapy development is hard enough. Finding the right support shouldn’t be.
We support academic laboratories, biotechs, and pharma companies through development and GMP challenges. Hands-on expertise, clear communication, and a genuine commitment to your success. Less uncertainty. Faster timelines. A partner you can rely on.
1000+
Clinical doses
manufactured in our GMP facility
15
Cell Types handled
T cells, NK cells, T regs, MSCs, iPS, immortalized cell lines…
50+
Development Programs
Process Development, Optimization, Scale up, Analytical & Potency test development
White Paper – From Bench to GMP: Building a Robust Manufacturing Process for Cell Therapies.
Great science is only the beginning. Discover why robust, scalable, and GMP-ready manufacturing processes have become critical to securing funding, accelerating development, and bringing cell therapies to patients. This white paper highlights the key strategies that transform promising research into investable and clinically viable products.
Cell-Based Therapies Are Not Conventional Drugs. They’re Living Treatments
Cell therapy programs fail more often from execution gaps than from bad science. Processes that aren’t robust, documentation that doesn’t hold up to scrutiny, timelines that slip when complexity hits. We work with our partners to close those gaps, bringing the technical depth and manufacturing expertise to keep your program on track from development through to clinical success.
Cell types handled: We handle both autologous and allogeneic, engineered (CAR/TCR) and non engineered (-T / -NK ; MSC/iPSc)
Technology agnostic: We operate independently of any specific platform or system, allowing us to adapt to your existing technologies and processes
Regulatory compliance: We ensure regulatory compliance at every stage, following ICH Q2 (R1), European Pharmacopeia, EMA/MHRA, and US Pharmacopeia standards, with a proven track record of successful audits.
CDMO Services To Accelerate Your Cell Therapy Development
Process Diagnostic
& Development
Analytical Development
cGMP Cell Banking
cGMP Manufacturing
Latest news
Stay on top of our latest breakthroughs.
Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges
Learn more: Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up ChallengesCell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies directly applicable to biotech and pharma iPSC programs. Toulouse, 2026 April 14th Tackling one of the main bottlenecks in iPSC-derived therapies Scale-up remains one of the most…
CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis
Learn more: CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic SclerosisCHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse).…
CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease
Learn more: CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s DiseaseCHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease Cell-Easy, a Contract Development and Manufacturing Organization (CDMO) specialized in advanced cell therapies, announces that its allogeneic adipose-derived mesenchymal stem cell product, CellReady®, will be investigated in a newly approved Phase 1 clinical trial for Alzheimer’s disease.…
They trusted us
Let’s talk about your project
Let’s turn your vision into a reality.
Phone: +33 534 276 550
Address: Cell-Easy SAS, 4 bis avenue Hubert Curien,
31100 Toulouse, France
Mail: info@cell-easy.com
